🟠 The study aims to address the common issue of lean mass reduction seen in #GLP1 #therapies, where up to 40% of weight lost is lean mass. 
#obesity #glp1 #weightloss #biotech @FDA $NVO $ALUR $SNY $SAN
#GLP1 #therapies #obesity #glp1 #weightloss #biotech #NVO #ALUR #SNY #SAN